Previous close | 0.0630 |
Open | 0.0600 |
Bid | 0.0000 x 1000 |
Ask | 0.0000 x 1800 |
Day's range | 0.0600 - 0.0650 |
52-week range | 0.0500 - 0.5395 |
Volume | |
Avg. volume | 91,525 |
Market cap | 2.897M |
Beta (5Y monthly) | 1.03 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.
Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.
Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.